Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 30, Issue 2, Pages 187-196Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfu104
Keywords
anemia; erythropoiesis; iron; iron deficiency; iron overload; kidney disease
Categories
Funding
- National Institute of Diabetes And Digestive And Kidney Diseases of the National Institutes of Health [R01DK093832, K25DK09600601]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK093832, K25DK096006] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The management of anemia in patients with chronic kidney disease (CKD) is difficult. The availability of erythropoiesis-stimulating agents (ESAs) has increased treatment options for previously transfusion-requiring patients, but the recent evidence of ESA side effects has prompted the search for complementary or alternative approaches. Next to ESA, parenteral iron supplementation is the second main form of anemia treatment. However, as of now, no systematic approach has been proposed to balance the concurrent administration of both agents according to individual patient's needs. Furthermore, the potential risks of excessive iron dosing remain a topic of controversy. How, when and whether to monitor CKD patients for potential iron overload remain to be elucidated. This review addresses the question of risk and benefit of iron administration in CKD, highlights the evidence supporting current practice, provides an overview of standard and potential new markers of iron status and outlines a new pharmacometric approach to physiologically compatible individualized dosing of ESA and iron in CKD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available